TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-derived mesenchymal stem cells, natural killer immune cells, and immune cell storage programs. In addition, the company manufactures and sells testing reagents, health food, and beauty products; and health and nutritional supplements. TCI GENE Inc. was founded in 2011 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does TCI GENE Inc. (6879) operate in?
TCI GENE Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is TCI GENE Inc. (6879) current stock price?
As of the latest data, TCI GENE Inc. stock price is NT$34.00, with a previous close of NT$34.00.
What is TCI GENE Inc. (6879) current market capitalization?
TCI GENE Inc. market cap is approximately 899.59 million.
What is TCI GENE Inc. (6879) Earnings Per Share (EPS)?
The trailing EPS is NT$1.52.
What is TCI GENE Inc. (6879) Price-to-Earnings (P/E) ratio?
TCI GENE Inc. current P/E ratio is 22.37.
Does TCI GENE Inc. (6879) pay dividends?
No. TCI GENE Inc. does not pay a dividend.
What is TCI GENE Inc. (6879) beta (volatility) score?
TCI GENE Inc. has a beta of 0.253, indicating lower volatility than the overall market.
